| COVID-19 Vaccine |
1 |
1 |
| Immunization |
0 |
0.91 |
| COVID-19 |
0 |
0.89 |
| Multiple Sclerosis |
0 |
0.99 |
| Vaccines |
0 |
0.36 |
| Biologic Therapy |
0 |
0.33 |
| Receptors |
0 |
0.28 |
| Blood |
0 |
0.11 |
| Immunoglobulin G (IgG) |
0 |
0.11 |
| Immunomodulator |
0 |
0.11 |
| Severe Acute Respiratory Syndrome |
0 |
0.11 |
| T-Lymphocyte |
0 |
0.1 |
| Acute Respiratory Distress Syndrome |
0 |
0.08 |
| California |
0 |
0.06 |
| Clinical Research |
0 |
0.06 |
| Disease-Modifying Therapy |
0 |
0.98 |
| Florida |
0 |
0.06 |
| Grant |
0 |
0.06 |
| Immunosuppressive Therapy |
0 |
0.06 |
| Lymphocytes |
0 |
0.06 |
| Monoclonal Antibody |
0 |
0.06 |
| Multiple Sclerosis Relapse |
0 |
0.06 |
| Polymerase Chain Reaction |
0 |
0.06 |
| Virginia |
0 |
0.06 |
| Healthcare and Medical Technology |
0 |
0.04 |